Inada K, Toi M, Yamamoto Y, Suzuki A, Kurisaki T, Suzuki H, Tominaga T
TOKYO METROPOLITAN KOMAGOME HOSP,DEPT SURG,BUNKYO KU,TOKYO 113,JAPAN. TOAGOSEI CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30033,JAPAN.
Oncol Rep. 1996 Jul;3(4):667-71. doi: 10.3892/or.3.4.667.
MDM2 once-protein is known to be involved in the inactivation of p53 and RE functions. We have investigated the expression of MDM2 protein in breast cancer by immunocytochemical analysis. Out of 103 primary tumors 39 (38%) showed positive nuclear staining of MDM2, although its gene amplification was infrequent. There was no correlation between MDM2 expression and various clinicopathological factors. However, MDM2 expression was significantly associated with expression of angiogenesis factors including vascular endothelial growth factor and platelet-derived endothelial cell growth factor. Anti-endothelial immunostaining demonstrated a correlation between MDM2 expression and the increment of intratumoral microvessel density. It is suggested that altered MDM2 protein expression might be involved in the promotion of angiogenesis in human breast cancer.
已知MDM2单次蛋白参与p53的失活和RE功能。我们通过免疫细胞化学分析研究了MDM2蛋白在乳腺癌中的表达。在103例原发性肿瘤中,39例(38%)显示MDM2核染色阳性,尽管其基因扩增并不常见。MDM2表达与各种临床病理因素之间无相关性。然而,MDM2表达与包括血管内皮生长因子和血小板衍生内皮细胞生长因子在内的血管生成因子的表达显著相关。抗内皮免疫染色显示MDM2表达与肿瘤内微血管密度的增加之间存在相关性。提示MDM2蛋白表达改变可能参与了人类乳腺癌血管生成的促进过程。